The human lung cancer cells require 100 times more of the mouse derived IL-1β to generate an IDO1/PD-L1 response that is seen with the human-derived IL-1β (Supplemental Fig. 3), indicating that further in vivo characterization needs to be performed in syngeneic or humanized mouse models. This evidence concerns the gene IDO1 and lung carcinoma.